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Purpose. Suppressor of cytokine signaling 7 (SOCS7) is a member of the SOCS family and is known to interact with phospholipase
C𝛾-1 (PLC𝛾-1), a key downstream mediator of the hepatocyte growth factor (HGF)/C-MET axis. Here, we report our observations
of the effect of knocking down SOCS7 gene on the behaviour of breast cancer cells both in vitro and in vivo and to elucidate
whether this involves HGF/C-MET pathway using the PLC𝛾-1 blocker U73122. Methods. MCF7 and MDA-MB-231 breast cancer
cells were transfected with anti-SOCS7 ribozymal transgene, to create sublines with SOCS7 knockdown. The in vitro growth and
migration of the cells were evaluated in basic conditions and with HGF and U73122 treatment using growth assays, scratch-wound,
and electrical cell impedance sensing (ECIS)migration assays.MCF7 andMDA-MB-231 in vivo tumour xenograft growth were also
studied. Results. Basal in vitro growth andmigration of both cellular lines and the in vivoMCF7 xenograft growth were significantly
enhanced with SOCS7 knockdown. In vitroHGF treatment has further influenced the growth andmigration when SOCS7 gene was
knocked-down in both cellular lines (𝑃 < 0.05). PLC𝛾-1 pharmacological inhibition of the HGF/C-MET cascade during their in
vitro growth andmigration seemed to only occur when SOCS7 genewas knocked down.Conclusions.We report a unique regulatory
role for SOCS7 in controlling themalignant behaviour of breast cancer linesMCF7 andMDA-MB-231 in vitro and theMCF7 tumour
xenografts in vivo. We also report a regulatory role for SOCS7 during the in vitroHGF-induced growth andmigration in these cells
as HGF treatment and SOCS7 loss have synergistically enhanced these functions. This SOCS7 knockdown-attributed effect could
be due to a precise anti-PLC𝛾-1 role.
1. Introduction
Suppressor of cytokine signalling 7 (SOCS7) is a member of
the SOCS family which has been implicated in the regulation
of many intracellular molecular mechanisms downstream of
cytokine and growth factor receptors. Among these regula-
tory functions of the SOCS family is a variably characterised
tumour suppressing role of some of its members. Only
recently a tumour suppressing role was described for SOCS7
particularly in breast cancer [1], and this intriguing role is still
under investigation.
Hepatocyte growth factor (HGF) is a multifunctional
cytokine that elicits diverse responses in different cells and
tissues. Much evidence now points to its drive of carcinogen-
esis and cancer invasion andmetastasis. HGF and its receptor,
C-MET, are both critical mediators of breast cancer progres-
sion, and, like in many other solid organ cancers, both HGF
and C-MET are highly expressed in breast cancer [2–5]. HGF
and C-MET expression correlates with mammary tumour
pathology, showing lowest expression levels in normal tissue
and benign hyperplasia while increasing in ductal carcinoma
in situ and showing highest expression in invasive breast
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carcinomas [6]. High HGF and C-MET expression levels
are now considered as independent prognostic indicators for
poor patient survival [4, 7].
In addition to its predictive expression in human mam-
mary tumours, HGF is a potent mammary tumour inducer
in mice, as targeted expression of HGF in mouse mammary
epithelium was found to lead to metastatic adenocarcinomas
[8]. Further reports showed that HGF/C-MET downstream
intermediate phospholipase C𝛾-1 (PLC𝛾-1) overexpression
was also observed in breast cancer [9], and specific PLC𝛾-1
inhibition was found to block breast cancer invasiveness [10].
Together these data support a role for
HGF/C-MET/PLC𝛾-1 route as a direct mediator in breast
cancer progression, thus making it a good target for
therapeutic intervention.
Historically, the SOCS7 variant (NAP4) was found to
directly interact with PLC𝛾-1, and other intermediates such
as NcK and Ash through the SOCS7-SH2 domain [11].
NcK is a cytoplasmic receptor tyrosine kinase adaptor
molecule [12, 13] which is involved in HGF/C-MET/PLC𝛾
signalling [14, 15].
Further reports have illustrated these SOCS7-NcK inter-
actions [16, 17] and a possible involvement of SOCS7 in cell
cycle arrest and in initiating the p53 apoptotic pathway [16].
The mediator Grb2 (otherwise known as Ash) is also
activated during the HGF/C-MET signalling leading to the
activation of downstream MAPK pathway involved in the
cellular proliferation and differentiation [18, 19] and can
also be involved in cellular invasion and motility through
activation of downstream FAK pathway [19]. SOCS7 can
interact with Grb2 at this level [11, 17, 20].
SOCS7 can also directly interact with p85, the regulatory
subunit of the HGF/C-MET downstream PI3K-AKT cascade
[16, 21], and JAK-STAT regulation by SOCS7 is also possible,
although not specifically reported inHGF/C-MET signalling.
For instance, as both STAT3 and STAT5 can be activated
downstream of HGF/C-MET through GAB1 [19], SOCS7 can
inhibit JAK2-STAT3 [11, 17, 20, 22], is known to interact with
STAT5 in vitro [23], and can alter the nuclear localisation of
pSTAT5 [24, 25].
Taken together, the above reports suggest a possible
multiregulatory involvement of SOCS7 in HGF/C-MET sig-
nalling. We here aimed to observe the effect of SOCS7
knockdown on the behaviour of breast cancer both in vitro
and in vivo and to investigate whether SOCS7 knockdown
in breast cancer cells MCF7 (ER +ve) and MDA-MB-231
(ER −ve) can affect their in vitro growth and migrational
responses when treated with HGF.
We hypothesised that SOCS7 is a negative regulator of
HGF effects, therefore predicting an additive effect of HGF
treatment and SOCS7 knockdown. A series of functional
assays were conducted in which we utilised HGF and the
specific pharmacological blockade of PLC𝛾-1 by using the
inhibitor U73122, to investigate whether SOCS7 regulates
the HGF/C-MET/PLC𝛾-1 axis by interacting with PLC𝛾-1
as U73122 blockade of PLC𝛾-1 would mitigate the anti-PLC
role of SOCS7. However, we did not intend to look into the
molecular details of SOCS7 interactions within this axis.
2. Materials and Methods
2.1. Cell Lines. Human breast cancer cells MCF7 and MDA-
MB-231 were purchased from the American Type Culture
Collection (ATCC, Maryland, US) and maintained in Dul-
becco’s modified Eagle’s medium supplemented with 10%
foetal calf serum (PAA Laboratories Ltd., Somerset, UK),
streptomycin and penicillin.The cells were incubated at 37∘C,
5% CO
2
and 95% humidity.
2.2. HGF and U73122. HGF was purchased from Sigma-
Aldrich (Poole, UK) and used in concentration of 40 ng/mL.
PLC𝛾-1 inhibitor (U73122) was purchased from Calbiochem
(Merck Chemicals Ltd., Nottingham, UK) and used in
concentration of 200 nM/L. A single dose of both agents
(HGF and U73122) was used to observe for occurrence of
the effect(s) on the cellular in vitro functions rather than
to quantify the magnitude of any possible effect. Targeting
the PLC𝛾-1 isoform with siRNA is probably more specific
than U73122, as the later has more pan anti-PLC function
including other PLC isoforms. However, in the context of this
study, we sought to observe the HGF stimulus effect through
the HGF/C-MET/PLC𝛾-1 cascade. Therefore, U73122 was
considered a reliable blocker of the PLC𝛾-1 activity, as other
PLC isoforms are not known to be involved in this pathway.
2.3. RNA Preparation and RT-PCR. Two groups of primers
were designed using Beacon Designer (PREMIER Biosoft
International, Palo Alto, CA, USA). The first group was
designed to amplify the coding sequence of SOCS7 gene
(Table 1); and the second category was designed according
to the secondary structure of SOCS7 gene transcript and
was used to synthesize a hammerhead ribozyme for the gene
silencing study (Table 2). Total RNA was extracted from cells
usingRNAextraction kit (AbGene Ltd., Surrey, England,UK)
and its concentration quantified using a spectrophotometer
(Wolf Laboratories, York, England, UK). cDNA was synthe-
sized using a first strand synthesis with an oligodt primer
(AbGene, Surrey, UK).The polymerase chain reaction (PCR)
was performed with the following conditions: 5min at 95∘C
and then 20 s at 94∘C-25 s at 56∘C, 50 sat 72∘C for 36 cycles,
and finally 72∘C for 7min. GAPDHwas amplified and used as
a house-keeping control. PCR products were then separated
on 0.8% agarose gel, visualized underUV light, photographed
using Unisave camera (Wolf Laboratories, York, England,
UK) and documented with Photoshop software.
2.4. Construction of Hammerhead Ribozyme Transgenes Tar-
geting Human SOCS7 (hSOCS7). To knockdown hSOCS7
gene (GenBank Accession: NM 014598.2), by using a ham-
merhead ribozyme transgene, we designed primers according
to secondary structure of the gene generated by using Zuker’s
RNAmFold programme, targeting at a specific GUC or AUC
site (Table 2). We synthesised ribozymes with a Touchdown
PCR procedure and cloned ribozymes into a mammalian
expression pEF6/V5-His-TOPO plasmid vector (Invitrogen
Ltd., Paisley, UK). SOCS7 ribozyme transgenes 1, 2, and 3 and
control plasmid vectors were then transfected into studied
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Table 1: Primers designed for amplifying the coding sequence of SOCS7.
Gene Name of primer Sequence of primers Optimal annealing temperature
SOCS7 Set 1 SOCS7 ExF1 5
󸀠-ATGGTGTTCCGCAACGTG 55∘C
SOCS7 R8 5󸀠-ACCAGGAAAGAACCATCTG
SOCS7 Set 2 SOCS7 F2 5
󸀠-CCGAAAGTT CTACTACTATGAT 55∘C
SOCS7 R8 5󸀠-ACCAGGAAAGAACCATCTG
SOCS7 Set 3 SOCS7 F8 5
󸀠-CTCAAAGTGCCTTTTCTCC 55∘C
SOCS7 R8 5󸀠-ACCAGGAAAGAACCATCTG
SOCS7 Set 4 SOCS7 F8 5
󸀠-CTCAAAGTGCCTTTTCTCC 55∘C
SOCS7 ExR1 5󸀠-CTACGTGGAGGGTTCCACCTCTT
SOCS7 Set 5 SOCS7 F8 5
󸀠-CTCAAAGTGCCTTTTCTCC 55∘C
SOCS7 ExR2 5󸀠-CTACGTGGAGGGTTCCACCTCT
SOCS7 Set 6 SOCS7 F8 5
󸀠-CTCAAAGTGCCTTTTCTCC 55∘C
SOCS7 ExR3 5󸀠-CTACGTGGAGGGTTCCACCTC
SOCS7 Set 7 SOCS7 F8 5
󸀠-CTCAAAGTGCCTTTTCTCC 56∘C
SOCS7 ExR4 5󸀠-CTACGTGGAGGGTTCCACCT
SOCS7 Set 8 SOCS7 F8 5
󸀠-CTCAAAGTGCCTTTTCTCC 56∘C
SOCS7 ExR5 5󸀠-CTACGTGGAGGGTTCCACC
SOCS7 Set 9 SOCS7 F8 5
󸀠-CTCAAAGTGCCTTTTCTCC 55∘C
SOCS7 ExR6 5󸀠-CTACGTGGAGGGTTCCA
Table 2: Primers for synthesis of the SOCS7 ribozymes 1, 2, 3.
Ribozyme Name of primer Sequence of primers
SOCS7 ribozyme-1 SOCS7 RIB1F 5
󸀠-CTGCAGGCGGCTGGGGCTGCGGAGGGGGCGGCTGAGGAGCTGATGAGTCCGTGAGGA
SOCS7 RIB1R 5󸀠-ACTAGTGGGGGTTGCTGCCCGTGTCCGTGTTTCGTCCTCACGGACT
SOCS7 ribozyme-2 SOCS7 RIB2F 5
󸀠-CTGCAGGGGGCGGCTGAGGAGCTGATGAGTCCGTGAGGA
SOCS7 RIB2R 5󸀠-ACTAGTCGGTGGGGGTTGCTGCCCGTGTTTCGTCCTCACGGACT
SOCS7 ribozyme-3 SOCS7 RIB3F 5
󸀠-CTGCAGGTGCTGTGGGGGTTGGCTGTGCAGGCTGATGAGTCCGTGAGGA
SOCS7 RIB3R 5󸀠-ACTAGTGCTCCCATCCGAGCAGCTGAATTTCGTCCTCACGGACT
cells, respectively, using electroporation. For electroporation,
we utilized the Easy Jet Plus system (Flowgen, Staffordshire,
UK), which passed a voltage of up to 310 volts across the cells
to produce small perforations in the cell wall integrity, thus
allowing passage of plasmid DNA across cell membranes to
be integrated into the cells.
For a transfection, 3 pg of plasmid DNA was added to
resuspended (−1 × 10∼) cells and mixed. The mixture was
left to stand at room temperature for 2 to 5 minutes. The
mixture was then transferred into an electroporation cuvette
(EuroGentech, Southampton, UK) ready for electroporation.
The cuvette was loaded into the electroporator and a pulse of
electricity (250–310 volts, depending on cell types)was passed
through the cuvette. The mixture was then immediately
(within 10 seconds) transferred into 10mL of prewarmed
culture medium (must be within 30 seconds). This reaction
was then cultured under the usual incubation conditions.
After 3-4 weeks selection with the antibiotic blasticidin
(5 𝜇g/mL), a stable cell line with the transgene was verified
by using RT-PCR for the success of knockdown before being
used in our experiments (Figure 1). This method has been
extensively used and reported previously in our laboratory
[22].
Six cellular sublines were established: SOCS7 knockdown
cells (MCF7ΔSOCS7 and MDA-MB-231ΔSOCS7), plasmid-only
control cells (MCF7pEF6 and MDA-MB-231pEF6), and the
wild-type, MCF7WT and MDA-MB-231WT. The knockdown
and plasmid-control cells were always kept in a maintenance
medium which contained 0.5𝜇g/mL blasticidin. Scrambled
ribozyme controls were used to discount any changes to the
gene expression profile that might result from the ribozymal
deliverymethod.We compared cDNAbands fromcells trans-
fected with scrambled ribozyme control and untransfected
cells and found no changes caused by ribozyme delivery.
2.5. In Vitro Cell Growth Assay. Cells suspension was
added into 96-well plates [2500 cells in 100 𝜇L HEPES (4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffering
medium per well]. For control wells, additional 100 𝜇L of
HEPES medium was added. Cells were allowed to adhere to
plate surface prior to treatment. 100𝜇L of an HGF containing
HEPES solution (40 ng/mL) was added to theHGF treatment
wells. When the PLC𝛾-1 inhibitor U732122 (1 𝜇M) was used,
cells were treated for 15 minutes prior to the addition of
HGF (40 ng/mL). These plates were incubated for 2 hours
at 37∘C before making the initial measurement (time point
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Figure 1: RT-PCR. Knocking down SOCS7 in MCF7 and MDA-
MB-231. The top two panels show the absence of SOCS7 cDNA
bands in cells transfected with SOCS7 ribozymes 1 and 2 vectors.
GAPDH was used as an internal control in the bottom panel.
0). Cells were fixed in 10% formaldehyde on the day of
plating and daily for the subsequent 4 days. 0.5% crystal
violet (w/v) was used to stain cells. Following washing
with dH
2
O twice and drying, the stained crystal violet was
dissolved with 10% (v/v) acetic acid and the absorbance of the
dissolved dye, corresponding to the number of viable cells,
was determined at a wavelength of 540 nm using an ELx800
spectrophotometer (BIO-TEK, ELx800, Wolf Laboratories,
York, England). Normalised cellular growth (proliferation)
rate was determined by the equation: (Absorbance at Day
4/Absorbance at Day 0) × 100%, where Day 0 is the day of
cell plating.
2.6. In Vitro Migration Scratch—Wounding Assay. Cells at a
density of 35,000 cells/200𝜇L/well were seeded into 24-well
plates and allowed to reach near confluence by incubation at
37∘C for 24 hours, then scratched with a pipette tip to create
wound size of approximately 200 𝜇m, and washed twice in
PBS to remove floating cells. When the PLC𝛾-1 inhibitor
U732122 (1 𝜇M) was used, cells were treated for 15 minutes
prior to the addition of HGF (40 ng/mL). The cells were
photographed at intervals using an inverted microscope; the
sizes of the wounds were subsequently analysed with the
TScratch software (ETH Zurich, 2008).
2.7. Electric Cell Substrate Impedance Sensing (ECIS) Assay.
ECIS-1600R model (Applied Biophysics, Inc., Troy, NY) was
used for migration modeling in wounding analysis [23].
8W10E arrays were used. Each of the 8 wells contains ten
circular 250𝜇m diameter active electrodes connected in
parallel on a common gold pad. Each well has a substrate area
of 0.8 cm2 and a maximum volume of 600 𝜇L. On average,
with a confluent cell layer, approximately 500–1000 cells will
be measured by the electrodes.
Following treating the array surface with a cysteine
solution (10mM), the arrays were incubated in a serum-free
medium (± HGF ± U73122) for 1 hour. The same number of
the respective cells (250,000 per well) was added to each well.
When confluencewas reached, themonolayerwas electrically
wounded at 6V AC and 4000KHz for 30 seconds. In vitro
migration rate was determined using the method previously
described [23].
2.8. In Vivo Growth Assay (for Assessment of In Vivo Devel-
opment of Mammary Tumours). Athymic nude mice (Nude
CD-1) of 4–6 weeks old were purchased from Charles River
Laboratories, Kent, UK, and maintained in filter-toped units.
Animals planned for MCF7 cell inoculation were implanted
with oestrogen pellets made of a mixture of 2mg of E2 and
18mg of cholesterol.
Breast cancer cells in culture flasks were first washed
using sterile BSS and treated using EDTA-Trypsin buffer.
After removing EDTA-Trypsin and washing, the single cell
suspension was prepared using serum free medium which
also contained 0.5mg/mL Matrigel. The cell number in the
suspension is 5 × 106/mL. 100 𝜇L of this cell suspension
(containing 0.5 million cells) was injected subcutaneously at
the left scapula area as previously described at our laboratory
[26].
Four groups were included: MCF7 empty plasmid vec-
tor/control transfection (pEF6), MCF7 with SOCS7 gene
knockdown (ΔSOCS7), MDA-MB-231 control transfection
(pEF6), and MDA-MB-231 with SOCS7 gene knockdown
(ΔSOCS7). Each tumour group included 6 athymic nude
mice. Mice were weighed and tumour sizes measured twice
weekly for 4weeks.Micewithweight loss over 25%or tumour
size larger than 1 cm in any dimension were terminated
according to the UK Home Office and UKCCCR guidelines.
The volume of the xenograft tumour was determined
using the formula:
Tumour Volume = 0.523 ×Width2 × Length. (1)
At the conclusion of the experiment, animals were
terminally anaesthetised; primary tumours were dissected,
weighed and frozen at −80∘C. Parts of the primary tumours
were fixed for future histological examination. Factors such
as tumour tissue oedema, necrosis, and the amount of
connective tissue will be further studied following a detailed
histological examination. This is in order to verify and
confirm that the tumour volume results correlate with the
lean tumour mass.
2.9. Statistical Analysis. Statistical analysis was performed
using SPSS version 16. Normality of data was tested by K-S
and Shapiro-Wilk tests, and homogeneity of variances was
tested by Levene’s test. For normal data, ANOVA and post-
hoc analysis was used for multiple comparisons, and two-
tailed student 𝑡-test for single two-sample comparisons. For
nonnormally distributed data, Kruksall-Wallis analysis was
used for multiple comparisons, and Mann-Whitney U test
was used for single two-sample comparisons. Results of cell
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growth and ECIS assays were presented asmean ± SE of three
independent experiments. RT-PCR and ECIS figures were
taken from representative experiments.
3. Results
3.1. Verification of SOCS7Gene Knockdown (Figure 1). Due to
the low expression of SOCS7 protein and the lack of a suitable
antibody, we were unable to detect SOCS7 by immunoblot.
However, SOCS7 gene knockdown in bothMCF7 andMDA-
MB-231 cells was confirmed at mRNA level using RT-PCR.
Successful knockdown was achieved using the designed anti-
SOCS7 ribozymes 1 and 2.
3.2. In Vitro Growth Assays (Tables 3 and 4; Figure 2). At
basic conditions and with SOCS7 knockdown, the MCF7
and MDA-MB-231 cellular in vitro growth appeared to be
significantly more than the control and wild-type growth.
In addition, HGF has produced a significant influence
on all MCF7 sublines. For instance, after 4 days of incu-
bation, in vitro growth of HGF-stimulated MCF7WT cells
was significantly larger than that of the unstimulated similar
subline or MCF7pEF6 (control) cells incubated for the same
duration. This was also true with HGF-stimulated MCF7pEF6
cells compared to unstimulated similar and wild-type cells.
Additionally,MCF7ΔSOCS7 cells treatedwithHGFhave shown
more growth than similar untreated cells.
MCF7ΔSOCS7 cellular growth following HGF treatment
was larger than that of HGF-treated wild-type and con-
trol cells. Pretreatment with the PLC𝛾-1 inhibitor (U73122)
appeared to abolish this growth difference as MCF7ΔSOCS7
cellular growth was no longer significantly larger than that
of MCF7WT and MCF7pEF6 cells when all three sublines were
treated with HGF and U73122.
Treatment of cells with HGF and U73122 has resulted
in abrogation of these HGF-induced growth effects in each
subline, and in the case of MCF7ΔSOCS7, U73122 seemed to
significantly block any HGF effect on their growth [1.3(0.25)
with HGF versus 0.85(0.02) with HGF and U73122; 𝑃 =
0.002].
In the case of MDA-MB-231 cells, HGF has produced
a significant influence on all their sublines. For instance,
after 4 days of incubation, in vitro growth of HGF-stimulated
MDA-MB-231WT cells was significantly larger than that of
a untreated similar subline or MDA-MB-231pEF6 (control)
cells incubated for the same duration. This was also true
with HGF-stimulated MDA-MB-231pEF6 cells compared to
unstimulated similar and wild-type cells. Additionally, HGF-
treated MDA-MB-231ΔSOCS7 cells have shown more growth
than similar untreated cells.
MDA-MB-231ΔSOCS7 cellular growth with HGF was
larger than the stimulated wild-type and control cells. As
with MCF7 cells, adding U73122 has abrogated this HGF-
mediated growth induction as MDA-MB-231ΔSOCS7 cellular
growth was no longer significantly larger than that of MDA-
MB-231WT and MDA-MB-231pEF6 cells.
3.3. In Vitro Scratch-Wound Migration Assays (Tables 5 and
6, Figures 3 and 4). At basic conditions and with SOCS7
knockdown, the MCF7 and MDA-MB-231 cellular in vitro
migration appeared to be significantly more than the control
and wild-type migration. With HGF treatment, stimulated
MCF7ΔSOCS7 migration was significantly better than that of
stimulated MCF7pEF6 cells. A positive synergistic influence
of HGF on each subline was also noted. For instance, HGF-
treated MCF7ΔSOCS7 migration was better than that of the
similar unstimulated subline, and HGF-treated MCF7pEF6
migration was significantly better than that of the sim-
ilar unstimulated subline. The pretreatment with U73122
has significantly blocked the stimulatory effect of HGF on
MCF7ΔSOCS7 migration but not that of the MCF7pEF6 cells
[59.8(20.3) versus 31.9(19.6); 𝑃 = 0.005 and 55.9(17.2) versus
54.7(15.5); 𝑃 = 0.9, resp.].
With HGF treatment, stimulated MDA-MB-231ΔSOCS7
migration was significantly better than that of stimulated
MDA-MB-231pEF6 cells. As with MCF7 cells, a positive
synergistic influence ofHGFon each sublinewas again noted.
For instance, stimulated MDA-MB-231ΔSOCS7 migration was
better than that of the similar untreated subline and stim-
ulated MDA-MB-231pEF6 migration was significantly better
than that of the similar untreated subline. The pretreatment
with U73122 has significantly abrogated the stimulatory effect
of HGF on MDA-MB-231ΔSOCS7 migration but not that of
theMDA-MB-231pEF6 cells [61.2(16.2) versus 34.87(3.8); 𝑃 =
0.007 and 71.8(4) versus 58.5(2); 𝑃 = 0.87, resp.].
3.4. In Vitro Electrical Cell Impedance Sensing (ECIS) Assays
(Tables 7 and 8, Figures 5 and 6). Unstimulated MCF7ΔSOCS7
migration was significantly more than that of both unstim-
ulated MCF7WT and unstimulated MCF7pEF6 cells. HGF-
treated MCF7ΔSOCS7 migration was significantly more than
that of treated control cells. Although the overall HGF effect
on MCF7 cellular migration was stimulatory, the HGF effect
was only significant enough in MCF7pEF6 migration but
not in MCF7ΔSOCS7. HGF-treated MCF7pEF6 migration was
significantly more than that of the similar untreated subline
[62.9(19.3) versus 37(17.6); 𝑃 = 0.026], while HGF-treated
MCF7ΔSOCS7 migration was slightly but insignificantly more
than that of similar untreated cells. The addition of U73122
has significantly limited the small stimulatory effect of HGF
on MCF7ΔSOCS7 migration but not that of the MCF7pEF6.
Similar to MCF7 cells, untreated (basal)
MDA-MB-231ΔSOCS7 migration was significantly more
than that of both untreated wild-type and control cells.
HGF-treated MDA-MB-231ΔSOCS7 migration was signif-
icantly more than that of treated MDA-MB-231pEF6 cells but
there was also a positive influence of HGF on each subline.
For instance, stimulated MDA-MB-231ΔSOCS7 migration was
more than that of the similar un-stimulated cells and stim-
ulated MDA-MB-231pEF6 migration was significantly more
than that of the similar unstimulated cells. The addition of
U73122 has significantly abrogated the stimulatory effect of
HGF on the migration of both sublines of MDA-MB-231.
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Table 3:The in vitro growth of MCF7 cells as measured by spectrophotometric light absorbance at a wavelength of 540 nm. Values represent
mean (SD).
Cell lines MCF7ΔSOCS7 𝑃
Incubation medium Serum free only
MCF7WT Serum free only 0.86 (0.12) vs. 0.54 (0.04) 0.037
MCF7pEF6 0.86 (0.12) vs. 0.58 (0.1) 0.009
HGF
MCF7WT HGF 1.3 (0.25) vs. 0.9 (0.1) 0.005
MCF7pEF6 1.3 (0.25) vs. 0.86 (0.1) 0.002
Pretreatment with U73122 then HGF
MCF7WT Pretreatment with U73122 then HGF 0.85 (0.02) vs. 0.74 (0.25) 0.4
MCF7pEF6 0.85 (0.02) vs. 0.71 (0.17) 0.26
Cell lines MCF7WT MCF7pEF6 MCF7ΔSOCS7 𝑃
HGF
MCF7WT
Serum free only
0.9 (0.1) vs. 0.54 (0.04) 0.86 (0.1) vs. 0.54 (0.04) 0.007 & 0.015
MCF7pEF6 0.9 (0.1) vs. 0.58 (0.1) 0.86 (0.1) vs. 0.58 (0.1) 0.015 & 0.03
MCF7ΔSOCS7 1.3 (0.25) vs. 0.86 (0.12) 0.002
Table 4: The in vitro growth of MDA-MB-231 cells as measured by spectrophotometric light absorbance at a wavelength of 540 nm. Values
represent mean (SD).
Cell lines MDAΔSOCS7 𝑃
Incubation medium HGF
MDAWT HGF 1.8 (0.04) vs. 1.3 (0.1) <0.001
MDApEF6 1.8 (0.04) vs. 1.4 (0.02) <0.001
Pretreatment with U73122 then HGF
MDAWT Pretreatment with U73122 then HGF 1.3 (0.07) vs. 1.2 (0.08) 0.49
MDApEF6 1.3 (0.07) vs. 1.2 (0.14) 0.73
Cell lines MDAWT MDApEF6 MDAΔSOCS7 𝑃
HGF
MDAWT
Serum free only
1.3 (0.1) vs. 0.9 (0.1) 1.4 (0.02) vs. 0.9 (0.1) <0.001 (both)
MDApEF6 1.3 (0.1) vs. 0.98 (0.05) 1.4 (0.02) vs. 0.98 (0.05) <0.001 (both)
MDAΔSOCS7 1.8 (0.04) vs. 1.3 (0.1) <0.001
For instance, the migration of MDA-MB-231pEF6 was signifi-
cantly limitedwithHGF andU73122 pre-treatment compared
to similar cells treated with HGF only [54.2(10.2) versus
104.2(36.1); 𝑃 = 0.046], and the migration of MDA-
MB-231ΔSOCS7 was also significantly limited with HGF and
U73122 pretreatment compared to similar cells treated with
HGF only [59.3(58.8) versus 222(48.1); 𝑃 < 0.001].
3.5. In Vivo Growth of the Mammary Tumours (Tables 9 and
10, Figure 7). In the CD-1 athymic nude mice model, it was
shown thatMCF7ΔSOCS7 tumour group grew at a significantly
faster pace compared to the control (MCF7pEF6) tumours.The
difference of tumour size was seen from early time points
(from 7 days onwards), and the overall difference between
MCF7ΔSOCS7 tumours and transfection control tumours were
highly significant (𝑃 < 0.001 by two-way ANOVA).
In regards to MDA-MB-231 mammary tumours, there
was no statistically significant overall difference in the
growth of MDA-MB-231 tumours with SOCS7 knockdown
compared to that of the transfection control group, even
though it appears that the control group tumours have grown
marginally bigger (𝑃 = 0.057 by two-way ANOVA).
4. Discussion
SOCS7, like other SOCS family members, is known to be
expressed by MCF7 and MDA-MB-231 cells [27, 28]. Under
basic conditions, several in vitro functions of MCF7 cells
seem to be significantly affected with SOCS7 knockdown,
namely, their growth and migration. Both in vitro growth
andmigration ofMCF7 cell lines were enhanced with SOCS7
knockdown, as was their in vivo xenograft growth in the
mouse model.This strongly suggests a critical role for SOCS7
in regulating these functions in MCF7 cells.
Data are less clear from MDA-MB-231 experiments.
Although their in vitro growth was enhanced with the SOCS7
knockdown, this was not mirrored during in vivo growth
studies. This is a reminder that in vitro conditions may not
represent the true pathophysiological environment in the
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Table 5: The in vitromigration of MCF7 as measured by relative wound area (%). Values represent Mean (SD).
Cell lines MCF7ΔSOCS7 𝑃
Incubation medium HGF
MCF7pEF6 HGF 31.9 (19.6) vs. 54.7 (15.5) 0.019
Cell lines MCF7pEF6 MCF7ΔSOCS7 𝑃
HGF
MCF7pEF6 Serum free only 54.7 (15.5) vs. 73.4 (9.8) 0.028
MCF7ΔSOCS7 31.9 (19.6) vs. 50.6 (5.9) 0.045
Pretreatment with U73122 then HGF
MCF7pEF6 HGF 55.9 (17.2) vs. 54.7 (15.5) 0.9
MCF7ΔSOCS7 59.8 (20.3) vs. 31.9 (19.6) 0.005
Table 6: The in vitromigration of MDA-MB-231 as measured by relative wound area (%). Values represent mean (SD).
Cell lines MDAΔSOCS7 𝑃
Incubation medium HGF
MDApEF6 HGF 34.9 (3.8) vs. 58.5 (2) 0.01
Cell lines MDApEF6 MDAΔSOCS7 𝑃
HGF
MDApEF6 Serum free only 58.5 (2) vs. 80.2 (4.5) 0.017
MDAΔSOCS7 34.9 (3.8) vs. 54.3 (8) 0.017
Pretreatment with U73122 then HGF
MDApEF6 HGF 71.8 (4) vs. 58.5 (2) 0.87
MDAΔSOCS7 61.2 (16.2) vs. 34.9 (3.8) 0.007
Table 7: The in vitromigration rate of MCF7 (𝜇m/hr). Values represent Mean (SD).
Cell lines MCF7ΔSOCS7 𝑃
Incubation medium HGF
MCF7pEF6 HGF 97 (18) vs. 62.9 (19.3) 0.008
Cell lines MCF7pEF6 MCF7ΔSOCS7 𝑃
HGF
MCF7pEF6 Serum free only 62.9 (19.3) vs. 37 (17.6) 0.026
MCF7ΔSOCS7 97 (18) vs. 83.9 (37.5) 0.252
Pretreatment with U73122 then HGF
MCF7pEF6 HGF 46.9 (14.2) vs. 62.9 (19.3) 0.184
MCF7ΔSOCS7 60.3 (21.6) vs. 97 (18) 0.005
Table 8: The in vitromigration rate of MDA-MB-231 (𝜇m/hr). Values represent Mean (SD).
Cell lines MDAΔSOCS7 𝑃
Incubation medium HGF
MDApEF6 HGF 222 (48.1) vs. 104.2 (36.1) <0.001
Cell lines MDApEF6 MDAΔSOCS7 𝑃
HGF
MDApEF6 Serum free only 104.2 (36.1) vs. 37.1 (2.6) 0.008
MDAΔSOCS7 222 (48.1) vs. 138.9 (13.9) <0.001
Pretreatment with U73122 then HGF
MDApEF6 HGF 54.2 (10.2) vs. 104.2 (36.1) 0.046
MDAΔSOCS7 59.3 (58.8) vs. 222 (48.1) <0.001
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Figure 2: (a) MCF7 in vitro growth (96 hours). (b) MDA-MB-231 in vitro growth (96 hours).
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Figure 3: (a) MCF7 scratch wound assay—with HGF/U73122. (b) Relative scratch-wound width area (%) of the MCF7 monolayer.
host body of the mouse model with all its growth factor
and cytokine crosstalk which may have led to a functional
redundancy of SOCS7 in these cells. Their in vitromigration,
however, was enhanced by SOCS7 knockdown under basal
conditions.
Recent studies suggested an influential role of SOCS7 in
regulating cellular division through its involvement in the
Septin-SOCS7-NcK axis. Cytoplasmic SOCS7 was found to
be involved in binding and translocating the adaptor protein
NcK to the nucleus to inhibit cellular division initiating cell
cycle arrest, in response to conditions such as DNA damage
[16]. NcK nuclear accumulation in turn leads to the activation
of p53 and its linked pathways. Hence, the loss of SOCS7 can
also be linked—through loss of p53 cascade activation—to
increased cancer cell proliferation. This uncontrolled in vitro
MCF7 and MDA-MB-231 growth with SOCS7 knockdown
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Figure 4: (a) MDA-MB-231 scratch wounding assay—with HGF/U73122. (b) Relative scratch-wound width area (%) of the MDA-MB-231
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Figure 5: (a) A representative ECIS wounding experiment to study in vitro migration rate of MCF7. ECIS time course following electrical
wounding (6V for 30 Sec). Wells: (1) MCF7WT (untreated); (2) MCF7ΔSOCS7 (+HGF); (3) MCF7pEF6 (+HGF/U73122); (4) MCF7ΔSOCS7
(untreated); (5) MCF7pEF6 (+HGF); and (6) MCF7ΔSOCS7 (+HGF/U73122). (b) In vitromigration of MCF7 sublines with and without HGF.
Table 9: MCF7 in vivo growth analysis (two-way ANOVA). Dependent variable: tumour size (MCF7).
Source Type III sum of squares Df Mean square 𝐹 Sig. Partial eta squared
Corrected model 27431.367a 19 1443.756 10.008 .000 .576
Intercept 90065.079 1 90065.079 624.337 .000 .817
Phenotype 4387.925 1 4387.925 30.417 .000 .178
Days 18976.157 9 2108.462 14.616 .000 .484
Phenotype ∗ days 4067.285 9 451.921 3.133 .002 .168
Error 20196.016 140 144.257
Total 137692.463 160
Corrected total 47627.384 159
a
𝑅 squared = .576 (adjusted 𝑅 squared = .518).
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Figure 7: In vivomammary tumour growth; (a) MCF7 tumours; (b) MDA-MB-231 tumours.
Table 10: MDA-MB-231 in vivo growth analysis (two-way ANOVA). Dependent variable: tumour size (MDA-MB-231).
Source Type III sum of squares Df Mean square 𝐹 Sig. Partial eta squared
Corrected model 296442.407a 19 15602.232 2.219 .005 .257
Intercept 268539.086 1 268539.086 38.200 .000 .238
Phenotype 25879.501 1 25879.501 3.681 .057 .029
Days 246104.941 9 27344.993 3.890 .000 .223
Phenotype ∗ days 20397.217 9 2266.357 .322 .966 .023
Error 857630.677 122 7029.760
Total 1444538.200 142
Corrected total 1154073.084 141
a
𝑅 squared = .257 (adjusted 𝑅 squared = .141).
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might therefore be the result of an unchecked cellular division
owing to the loss of SOCS7-NcK and p53 regulatory role in
cellular division.
In this study we hypothesised a regulatory role for SOCS7
in HGF/C-MET signalling in breast cancer based on its mul-
tiple interactions with intermediate molecules downstream
of the C-MET receptor. The most important of these is the
PLC𝛾-1 and NcK, both were reported to form a complex with
the activated receptor [14], and our previous data showed a
specific anti-PLC𝛾 role for SOCS7 in IGF-I signalling [28].
The knockdown of SOCS7 would not have increased the C-
METor the PLC𝛾-1 expression as their expression in thewild-
type MCF7 andMDA-MB-231 cells is already strong [29, 30].
Our observations here do indeed support this hypothesis
in the in vitro environment. For instance, we observed that
HGF has produced a positive influence on the growth of all
MCF7 sublines (control and knockdown) but producedmore
significant influence on the MCF7ΔSOCS7 cells compared to
HGF-treated wild-type or control cells. These growth effects
appeared to be affected by pretreatment with the PLC𝛾-1
inhibitor, U73122, as any significant HGF-induced growth
difference between MCF7ΔSOCS7, control and wild-type cells
has become negligible. Similar observations were seen during
MDA-MB-231 in vitro growth assay. These observations may
indicate that in addition to the expected HGF positive effect
on the growth and proliferation of MCF7 and MDA-MB-
231 cells in vitro, this effect was synergistically enhanced
with the knockdown of SOCS7 gene, but as this growth
difference between knockdown sublines and the control
sublines became abrogated with U73122, this may indicate a
specific role for SOCS7 in the HGF/PLC𝛾 proliferation axis.
Using scratch-wound and ECIS assays, we observed that
MCF7ΔSOCS7 and MDA-MB-231ΔSOCS7 cells under the HGF
stimulus had demonstrated a more enhanced migration than
did stimulated control cells (𝑃 < 0.05). We also observed
a rate of migration of MCF7ΔSOCS7 cells slightly higher (but
with no statistical significance) following HGF treatment
than that of similar unstimulated cells and significantly
higher than that of similar cells treatedwithHGF andU73122.
MDA-MB-231ΔSOCS7 migration followed a very similar pat-
tern with all differences statistically significant (𝑃 < 0.05).
These migration data showed an additive influence of HGF
treatment and SOCS7 knockdownon the in vitromigration of
both breast cancer lines. They also showed that such additive
influence due to SOCS7 knockdown was lost with U73122
treatment, which may point to a precise anti-PLC𝛾-1 role for
SOCS7.
5. Conclusion
SOCS7 knockdown can result in increased MCF7 andMDA-
MB-231 basal cellular growth and migration in vitro and
can positively influence the growth of MCF7 in vivo tumour
xenografts in nude athymic mice. This is suggestive of a
tumour suppressive role for this molecule in MCF7 breast
cancer cells. No similar growth results were shown from the
MDA-MB-231 cellular in vivo growth observations. SOCS7
knockdown, however, has enhanced the MDA-MB-231 cel-
lular migration.
We also postulate a significant involvement of SOCS7
in the HGF/PLC𝛾-1 regulation. SOCS7 loss has resulted in
the amplification of HGF/C-MET growth and migrational
signalling in the two studied breast cancer cell lines, but
pharmacological blockade of PLC𝛾-1 enzymatic activity has
mitigated this amplified signalling. This could mean that
SOCS7 is involved very precisely in the regulation of PLC𝛾-1
function.
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